B. Riley Boosts Earnings Estimates for Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Equities research analysts at B. Riley lifted their Q1 2025 EPS estimates for shares of Eton Pharmaceuticals in a research note issued on Sunday, April 27th. B. Riley analyst M. El-Saadi now expects that the company will earn $0.13 per share for the quarter, up from their previous estimate of $0.06. B. Riley currently has a "Buy" rating and a $24.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals' current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals' Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at $0.11 EPS, FY2025 earnings at $0.64 EPS, FY2026 earnings at $1.48 EPS, FY2027 earnings at $1.86 EPS, FY2028 earnings at $2.23 EPS and FY2029 earnings at $2.46 EPS.

A number of other analysts have also weighed in on the company. Craig Hallum raised their target price on Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, March 19th. HC Wainwright restated a "buy" rating and issued a $33.00 price objective on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th.

Eton Pharmaceuticals Stock Up 2.2 %

ETON traded up $0.37 during trading on Wednesday, hitting $17.34. The company's stock had a trading volume of 239,854 shares, compared to its average volume of 180,687. The stock has a market capitalization of $465.02 million, a price-to-earnings ratio of -78.82 and a beta of 1.22. The firm's 50 day moving average price is $14.28 and its two-hundred day moving average price is $13.25. Eton Pharmaceuticals has a 12 month low of $3.18 and a 12 month high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.02). The company had revenue of $11.65 million during the quarter, compared to analysts' expectations of $10.53 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%.

Institutional Investors Weigh In On Eton Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. increased its position in Eton Pharmaceuticals by 18.3% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company's stock worth $141,000 after purchasing an additional 1,634 shares during the period. XTX Topco Ltd grew its position in shares of Eton Pharmaceuticals by 29.6% during the 4th quarter. XTX Topco Ltd now owns 14,655 shares of the company's stock worth $195,000 after buying an additional 3,351 shares during the period. Tower Research Capital LLC TRC acquired a new stake in shares of Eton Pharmaceuticals during the 4th quarter worth approximately $86,000. Jefferies Financial Group Inc. bought a new stake in shares of Eton Pharmaceuticals during the fourth quarter worth approximately $133,000. Finally, Bank of America Corp DE lifted its holdings in Eton Pharmaceuticals by 5,422.4% in the fourth quarter. Bank of America Corp DE now owns 11,100 shares of the company's stock valued at $148,000 after buying an additional 10,899 shares during the period. Institutional investors own 27.86% of the company's stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.